Skip to NavigationSkip to content


Celgene plays catch up with $1.4 billion immunotherapy deal

Those commentating on Celgene’s latest deal seem to be equally divided between two camps: it is too much money, too late, and those that think it might be a gamble that can pay off. The deal itself is a licensing agreement with BeiGene for its PD-1 immunotherapy, BGB-A317; it is structured so that BeiGene receives $263 million upfront, a further $150 million equity stake and close to $1 billion locked into milestone agreements.

BeiGene to develop $330 million biologics plant

BeiGene, a Chinese biotech company, and Guangzhou GET Technology Development, an affiliate of Guangzhou Development District, will partner in the development deal to construct a commercial scale biologics manufacturing site in Guangzhou, China. The deal sees Guangzhou GET contribute $150 million in cash while BeiGene will provide $30 million, the rest of the $150 million will be provided through commercial loans.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches